EUVIMEDEUVIMED entdecken
Crossref

Protein Kinase C Inhibition Overcomes Targeted Therapy Resistance in Cutaneous Melanoma

Corinne I Stoffel iD, Ossia Eichhoff iD, Phil F Cheng iD, Luzia Seiler iD, Flavia Tellenbach iD, Andreas Dzung iD, Francesca Chiovaro iD, Reinhard Dummer iD, Mitchell P Levesque iD

Experimental Dermatology · 2025

DOI: 10.1111/exd.70093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Dermatology, 2025. Verfasst von Corinne I Stoffel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Melanoma, Protein Kinase C, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

WNT5a expression is associated with a MAPK inhibitor resistant phenotype in melanoma driving cell polarity and invasion. No small molecules specifically targeting WNT5a are available. Promising results of targeting non‐canonical WNT5a‐dependent WNT signalling with a pan‐PKC inhibitor in uveal melanoma prompted us to investigate the relevance of PKC inhibition in cutaneous melanoma. We revealed PKC signalling and WNT5a expression to be associated in a positive feedback loop, suggesting pan‐PKC inhibitor as a potent inhibitor of WNT5a in cutaneous melanoma. Combinatorial PKC and MAPK pathway inhibition significantly reduced proliferation and invasion by induction of apoptosis in targeted therapy‐resistant melanoma in vitro. In in vivo xenograft studies, we found less proliferation and apoptosis induction in the PKC inhibitor single and combination treatment group with MAPK pathway inhibitors than in the standard of care treatment group. Thus, targeting the non‐canonical WNT signalling pathway via combinatorial PKC and MAPK pathway inhibition is beneficial for therapy‐resistant cutaneous melanoma combating tumour heterogeneity in vivo. With our study, we are providing an alternate treatment strategy we think is worth investigating as future clinical interventions in cutaneous melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmMelanomaProtein Kinase CProtein Kinase InhibitorsSkin NeoplasmsAnimalsHumansMiceApoptosisCell Line, TumorCell ProliferationMAP Kinase Signaling SystemWnt Signaling PathwayWnt-5a ProteinXenograft Model Antitumor Assays

Stichwörter der Autor:innen

PKCWNT signallingcutaneous melanomaphenotype switchingresistancesotrastaurin

Substanzen

Protein Kinase CProtein Kinase InhibitorsWnt-5a ProteinWNT5A protein, human

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • InSphero AG, Schlieren, Switzerland.

ORCID-Profile: Corinne I Stoffel, Ossia Eichhoff, Phil F Cheng, Luzia Seiler, Flavia Tellenbach, Andreas Dzung, Francesca Chiovaro, Reinhard Dummer, Mitchell P Levesque

Zitieren

APA

Stoffel, C. I., Eichhoff, O., Cheng, P. F., Seiler, L., Tellenbach, F., Dzung, A., Chiovaro, F., Dummer, R., & Levesque, M. P. (2025). Protein Kinase C Inhibition Overcomes Targeted Therapy Resistance in Cutaneous Melanoma. Experimental Dermatology. https://doi.org/10.1111/exd.70093

Vancouver

Stoffel CI, Eichhoff O, Cheng PF, Seiler L, Tellenbach F, Dzung A, et al. Protein Kinase C Inhibition Overcomes Targeted Therapy Resistance in Cutaneous Melanoma. Experimental Dermatology. 2025. doi:10.1111/exd.70093

BibTeX
@article{Stoffel2025,
  author = {Stoffel, Corinne I and Eichhoff, Ossia and Cheng, Phil F and Seiler, Luzia and Tellenbach, Flavia and Dzung, Andreas and Chiovaro, Francesca and Dummer, Reinhard and Levesque, Mitchell P},
  title = {Protein Kinase C Inhibition Overcomes Targeted Therapy Resistance in Cutaneous Melanoma},
  journal = {Experimental Dermatology},
  year = {2025},
  doi = {10.1111/exd.70093}
}
Kostenlos starten →